The effect of vitamin D administration on treatment of anemia in ESRD patients with vitamin D deficiency on hemodialysis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201505152417N17

Enrollment

Registered

2016-08-11

Start date

2014-10-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. End Stage Renal Disease

Interventions

Intervention 1: Intervention group: Pearl vitamin D 50000 IU, weekly for 12 weeks and after 3 weeks, manufactured by Zahravi company. Intervention 2: Control group: Pearl placebo, weekly for 12 weeks

Treatment - Drugs

Placebo

Intervention group: Pearl vitamin D 50000 IU, weekly for 12 weeks and after 3 weeks, manufactured by Zahravi company

Control group: Pearl placebo, weekly for 12 weeks and after 3 weeks, manufactured by Zahravi company

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with renal failure on hemodialysis for 3 months at least; Patients with hemoglobin concentration Lower than 12 g/dl; Patients with vitamin D deficiency (25(OH) vit D < 30 ng/ml); Exclusion criteria: Patients with serum calcium level more than 9.5mg/dL; Patients with serum Phosphate level more than 5.5mg/dL; Non-compliant patients; Patients who were treated by medications that could affect their Hb level such as immunosuppressants.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum 25 OH vitamin D level. Timepoint: At begining, end of 2 and 4 months. Method of measurement: ELISA, ng/mL.;Serum ferritin level. Timepoint: Monthly. Method of measurement: ELISA, mg/dL.;Serum Hemoglobin level. Timepoint: Monthly. Method of measurement: Cell counter, g/dL.;Erythropoietin dose requirement. Timepoint: Weekly. Method of measurement: Mathematically.	—

Secondary

Measure	Time frame
Serum calcium level. Timepoint: Monthly. Method of measurement: ELISA, mg/dL.;Serum albumin level. Timepoint: Monthly. Method of measurement: ELISA, g/dL.;Serum adiponectin level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.;Serum leptin level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.;Serum ICAM level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.;Serum VCAM level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.	—

Measure

Time frame

Serum calcium level. Timepoint: Monthly. Method of measurement: ELISA, mg/dL.;Serum albumin level. Timepoint: Monthly. Method of measurement: ELISA, g/dL.;Serum adiponectin level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.;Serum leptin level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.;Serum ICAM level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.;Serum VCAM level. Timepoint: Begining and after 4 months. Method of measurement: ELISA.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Firouzeh Moeinzadeh

Isfahan University of Medical Sciences

moinzade@resident.mui.ac.ir+98 31 3620 2020

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026